Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) showed monthly volitility of 4.55%
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) showed monthly volitility of 4.55%
21 Abril, 2017, 02:16
The stock subtracted in the prior trading session by -3.22%, closing at the stock price of $48.74. Following the completion of the transaction, the insider now directly owns 21,403 shares of the company's stock, valued at approximately $1,177,165. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Agios Pharmaceuticals Inc (NASDAQ:AGIO) shares were trading -25.66% below from the 52-week high mark of $67.74 and 40.51% above from the 52-week bottom of $35.84. Although past volatility action may help predict the future volatility of a stock, it may also be greatly different when taking into account other factors that may be driving price action during the period of time.
On Thursday, March 23rd, Lewis Clayton Jr. It worsened, as 23 investors sold Agios Pharmaceuticals Inc shares while 45 reduced holdings. Finally, Canaccord Genuity set a $90.00 price objective on shares of Agios Pharmaceuticals and gave the stock a "buy" rating in a report on Thursday, February 16th.
Agios Pharmaceuticals Inc (NASDAQ:AGIO) CEO David P. Schenkein sold 3,000 shares of the business's stock in a transaction dated Monday, April 3rd. The company has a 50 day moving average of $53.57 and a 200-day moving average of $50.52.
Currently, the analyst consensus on Agios Pharma is Strong Buy and the average price target is $62.50, representing a 24.1% upside. Typically, a stock scoring an 8 or 9 would be seen as strong while a stock with a score from 0-2 would be viewed as weak. (NASDAQ:AGIO) are -9.13%; -13.21% for the month; 14.23% for the last quarter; 2.57% for the past six-months; and -1.28% for the last 12 months. The biopharmaceutical company reported ($1.34) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($1.51) by $0.17. Rhumbline Advisers boosted its stake in Agios Pharmaceuticals by 3.4% in the third quarter. Likewise, the positive performance for the quarter was recorded as 6.19% and for the year was 33.18%, while the YTD performance remained at 15.85%.
EPS growth in next year is estimated to reach 18.60% while EPS growth estimate for this year is set at -61.30%. Agios Pharmaceuticals, Inc. (AGIO) reported that it has priced an underwritten a public offering of 5,050,505 shares of common stock at a price to the public of $49.50 per share, before underwriting discounts, which would result in aggregate gross proceeds of around $250 million.
Agios Pharmaceuticals, Inc.is a clinical-stage biopharmaceutical company. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and worldwide copyright laws.
Among 7 analysts covering VCA Antech (NASDAQ:WOOF), 3 have Buy rating, 0 Sell and 4 Hold.
A number of research firms have issued reports on AGIO.
08/19/2016 - BTIG Research began new coverage on Agios Pharmaceuticals, Inc. giving the company a " rating.
The stock of Agios Pharmaceuticals Inc (NASDAQ:AGIO) gapped down by $0.18 today and has $48.45 target or 5.00% below today's $51.00 share price.
Among 13 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 8 have Buy rating, 0 Sell and 5 Hold. They now have a United States dollars 46 price target on the stock. After $-1.34 actual EPS reported by Agios Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 36.57% negative EPS growth. First Mercantile Trust Co. purchased a new stake in Agios Pharmaceuticals during the third quarter valued at $137,000. About 514,845 shares traded or 20.26% up from the average. Capital International Ltd. CA raised its stake in shares of Agios Pharmaceuticals by 31.0% in the fourth quarter.
06/13/2016 - Agios Pharmaceuticals, Inc. was upgraded to " by analysts at JP Morgan. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Guardiola's men also have the FA Cup to look forward to, with a game against Arsenal scheduled in the semi-finals next weekend. Shane Long, 28, will be a threat to Manchester City while Nathan Ward , 23, is emerging as a real talent for his team.
Fans had been concerned that the broadcaster would cut some content, such as the baking history segments, to accommodate adverts. C4's version of the former BBC baking competition is taking shape, with bosses recently unveiling its new hosting line-up.
Pakistani politicians of all stripes have over the years been accused of corruption , which remains endemic. The two judges ruled against PM Nawaz Sharif , whereas the other three were in favour of forming a JIT.
How bad could it be? If the polls are correct, the election would see the Tories winning 375 seats with a 100-seat majority . While Labour may be demoralized and divided under Corbyn's leadership, it doesn't look like he is going anywhere fast.
Despite those changes on the local and state level, the federal government continues to categorize marijuana as a Schedule I drug. A June 2015 Fairleigh Dickinson University/Public Mind Poll found 49 percent support personal pot use, 46 percent opposed it.
When the "for sale" sign went up on the Valley Car Wash in Parachute , Colo., Mark Smith didn't waste a second. It rescinded the ban two years later after revenues from natural gas dropped, according to local media.
Pence said after the meeting that Trump believes it is in America's interest to negotiate economic deals on a bilateral basis. North Korea did test a missile on Sunday, but by United States and South Korean accounts it failed "within seconds".
Finally, New Capital Management LP bought a new position in Chevron during the fourth quarter valued at approximately $171,000. Scotiabank set a $114.00 target price on Chevron and gave the stock a "buy" rating in a research report on Monday, March 27th.
North and South Korea are technically still at war because their 1950-53 conflict ended in a truce, not a peace treaty. The next step would be to bring home the 54,000 US troops stationed in Japan and another 25,000 troops in South Korea.
Local police and administrative officials rushed to the spot and pacified the situation. The students later blocked traffic on the highway near Banihal.
Betting tips on a draw in football
They are fighting, especially in spring and summer, motivated teams- those who want to get into European Cups or avoid relegation. For an expert, it is a reason to ensure a stable income with the competent rates combined with rational management of the bank.
Kylian Mbappe: Monaco don't want to avoid anyone
Whatever the reasons behind the travel issues, there was nothing but support for Dortmund inside the ground. That forced the match at the Stade Louis II to kick off five minutes later than planned.
News Review GNC Holdings Inc (NYSE:GNC), Snap Inc (NYSE:SNAP)
The stock of GNC Holdings Inc (NYSE: GNC ) gapped up by $0.97 today and has $9.88 target or 8.00% above today's $9.15 share price. TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Markets Daily and is the property of of Markets Daily.
Study links soda (diet or not) and sugary juice to dementia
Yet another study showed that artificial sweeteners alter bacteria in the gut, which might also have a negative effect, Pase said. Notably, data collection did not distinguish between the types of artificial sweeteners used in the beverages.
Trump tells Kim Jong-Un: Behave
Chinese Foreign Minister Wang Yi repeated China's position that the crisis could only be resolved by diplomacy. North Korea's vice foreign minister Han Song Ryol told BBC that missiles will be tested weekly.
GOP's John Kasich featured guest at live town hall on CNN
File- CNN is set to host a town hall with OH governor and former Republican presidential candidate John Kasich on Monday. His new book strikes a similar tone by outlining his hopes for the future and sharing his concerns for America.